Gazyva (obinutuzumab) for Non-oncologic Uses
Customize your policy alerts
Sign up for Bluecross Idaho Policy 5.01.501 alerts
Get alerted when Policy 5.01.501 changes without checking for updates manually.
Monitor payer policy activity
Defines medical benefit coverage and prior authorization criteria for intravenous obinutuzumab when used for non-oncologic indications, primarily for treatment of active lupus nephritis in adults; applies to Bluecross Idaho members subject to their specific benefit plans.
New policy added to prescription drug section for Gazyva for treatment of active lupus nephritis in those with systemic lupus erythematosus.
Coverage Criteria for Gazyva (obinutuzumab)
inv-01: Initial Therapy
Covered when ALL of the following are met:
inv-02: Continuation Therapy
Continuation requests are covered when ALL of the following are met:
inv-03: Initial and Continuing Therapy (summary)
Policy includes coverage criteria for initial and continuing treatment of active lupus nephritis with Gazyva as adopted by Blue Cross of Idaho.
See main policy sections for full criteria text.
IV obinutuzumab is considered investigational for all non-oncologic indications other than the specific indications addressed in this policy (see criteria for active lupus nephritis).
Inclusion of a billing or diagnostic code in the policy materials does not guarantee coverage. Coverage determinations are subject to the member-specific benefit plan documentation and the terms and conditions of the applicable plan, as well as any other applicable policies or legal requirements.
Use of intravenous obinutuzumab (Gazyva) for non-oncologic indications other than active lupus nephritis is considered investigational and is not covered under this policy.
Within this document segment there are no explicit statements labeled as 'not medically necessary.'
Coding and Clinical Thresholds
| No codes listed |
| J9301 | Injection, obinutuzumab, 10 mg (Gazyva) |
| M32.0 - M32.9 | Systemic lupus erythematosus (SLE) |
Provider Actions, Documentation, and Authorization
Prior authorization required for non‑oncologic Gazyva
Prior authorization is required for intravenous Gazyva (obinutuzumab) when requested for non-oncologic indications and will be evaluated against the policy's initiation and continuation criteria. Oncologic uses are evaluated per NCCN and oncology policy guidance.
Authorization required — submit diagnosis and drug codes
This is a new prescription drug policy for Gazyva for treatment of active lupus nephritis; submit the appropriate diagnosis coding (ICD‑10 M32.0‑M32.9) and the HCPCS code for obinutuzumab (J9301) when requesting authorization.
Combination therapy required; concomitant biologics prohibited
Gazyva must be administered in combination with a standard immunosuppressive therapy regimen for active lupus nephritis and must not be used in combination with any other biologic DMARD, targeted synthetic DMARD, or other immunomodulator.
Example concomitant and prior DMARDs (lists provided)
The policy provides example lists of conventional, biologic, and targeted synthetic DMARDs to reference when documenting concomitant therapies or prior treatments.
- Conventional DMARD examples: azathioprine, cyclophosphamide, cyclosporine, hydroxychloroquine, leflunomide, methotrexate, mycophenolate, sulfasalazine
- Biologic DMARD examples: abatacept, adalimumab, anakinra, infliximab, rituximab, etc.
- Targeted synthetic DMARD examples: apremilast, baricitinib, deucravacitinib, tofacitinib, upadacitinib
Clinical documentation required for authorization
Required clinical documentation for authorization requests must include the patient's age, SLE diagnosis per American College of Rheumatology criteria, and kidney biopsy demonstrating active lupus nephritis Class III or IV (with or without Class V); also include autoantibody results, current immunosuppressive regimen, and prescriber specialty.
- Autoantibody documentation: ANA above laboratory reference range OR anti‑dsDNA above reference range (or >2× reference if ELISA)
- Prescriber specialty: rheumatologist or nephrologist, as appropriate
- Current standard immunosuppressive LN therapy (e.g., azathioprine, cyclophosphamide, glucocorticoids, mycophenolic acid analogs)
Coding guidance — use M32.x and J9301
When submitting authorization requests, document the diagnosis of systemic lupus erythematosus using ICD‑10 codes M32.0–M32.9 and include the applicable HCPCS code for obinutuzumab (J9301) as coding guidance.
Denial triggers — criteria not met or investigational uses
Requests that do not meet the medical necessity criteria for active lupus nephritis (either initiation or continuation criteria) or requests for other non‑oncologic uses of IV obinutuzumab may be denied.
- IV obinutuzumab is considered investigational for all other non‑oncologic indications
Coverage determinations subject to member benefit plan
Coverage determinations are subject to the member's specific benefit plan documentation and additional terms and conditions; inclusion of a code in this policy does not guarantee coverage or payment.
Key Definitions
Background
Obinutuzumab (Gazyva) is an anti-CD20 monoclonal antibody that depletes B cells through multiple mechanisms, including immune effector functions, induction of direct cell death, and complement-dependent cytotoxicity. It is FDA-approved for certain hematologic malignancies and, per this policy, is addressed for use in combination with standard immunosuppressive therapy for treatment of active lupus nephritis.
Policy Revision History
Blue Cross of Idaho adopted a new prescription drug policy for Gazyva (obinutuzumab) for treatment of active lupus nephritis; policy to be effective 2026-06-01 and includes initial and continuing treatment criteria.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.